AdaptHealth (AHCO) expects "minimal impact" from tariffs in 2025, and the diabetes segment "appears to be turning a corner," RBC Capital Markets said in a report.
Discussions with AdaptHealth's "manufacturing partners have not indicated that tariffs are likely to pose a significant issue," the report said.
The diabetes segment turnaround seems to be "underway with new starts improving sequentially in two consecutive quarters," and the resupply attrition rate was the lowest in two years, RBC said.
AdaptHealth's Q1 sleep segment revenue fell 3% as setups came in "slightly below management expectations" at 113,000, RBC said.
Management is launching a "scheduling system to reduce friction for new setups, alongside other strategic tools to combat the competitive environment," the report said.
RBC cut its price target on AdaptHealth stock to $13 from $14, citing "industry multiple compression," and reiterated its outperform rating.
Price: 8.51, Change: +0.28, Percent Change: +3.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。